# MENS (Jyong Biotech Ltd.) - SEC EDGAR Financial Statements

> Jyong Biotech Ltd. reported $20.78M in total assets and a net loss of $4.67M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/MENS
- Markdown: https://convexityos.com/fundamentals/MENS.md
- SEC CIK: 0001954488
- Reporting currency: USD
- Latest filing period: December 31, 2025
- Last synced: Nov 20, 2026, 05:47 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001954488&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$2.61M | Operating profit |
| Net Income | FY 2025 | -$4.67M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$0.06 | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Dec 31, 2025 | $1.18M | Total debt: $15.44M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Research & Development | $813K | $927K | $1.07M |
| Selling, General & Admin | $1.79M | $1.13M | $1.73M |
| Total Operating Expenses | $2.61M | $2.06M | $2.80M |
| **Operating Income** | -$2.61M | -$2.06M | -$2.80M |
| **EBITDA** | -$2.51M | -$1.94M | -$2.67M |
| Interest Income | $610K | $7.0K | $56K |
| Interest Expense | $2.54M | $1.03M | $757K |
| Income Before Tax | -$4.67M | -$3.02M | -$4.40M |
| **Net Income** | -$4.67M | -$3.02M | -$4.40M |
| Basic EPS | -$0.06 | -$0.04 | -$0.06 |
| **Diluted EPS** | -$0.06 | -$0.04 | -$0.06 |
| Basic Shares Outstanding | 73.0M | 71.6M | 71.6M |
| Diluted Shares Outstanding | 73.0M | 71.6M | 71.6M |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| Cash & Cash Equivalents | $1.18M | $98K |
| **Cash & Short-Term Investments** | $1.18M | $98K |
| **Total Current Assets** | $15.54M | $206K |
| Property, Plant & Equipment, Net | $3.09M | $3.05M |
| Other Non-Current Assets | $6.0K | $6.0K |
| **Total Non-Current Assets** | $5.24M | $6.16M |
| **Total Assets** | $20.78M | $6.37M |
| Accounts Payable | $2.0K | $3.0K |
| Short-Term Debt | $15.34M | -- |
| Other Current Liabilities | $3.45M | $3.29M |
| **Total Current Liabilities** | $34.81M | $12.13M |
| Other Non-Current Liabilities | $60K | $58K |
| **Total Non-Current Liabilities** | $10.87M | $30.76M |
| **Total Liabilities** | $45.68M | $42.88M |
| **Total Debt (incl. Leases)** | $15.44M | $175K |
| Common Stock | $1.0K | $1.0K |
| Retained Earnings | -$37.75M | -$33.08M |
| Accumulated Other Comp. Income | $682K | $1.12M |
| **Total Stockholders' Equity** | -$24.91M | -$36.52M |
| Total Equity | -$24.91M | -$36.52M |

### Balance Sheet (Quarterly)

| Line Item | Dec 2025 | Dec 2024 |
| --- | --- | --- |
| Cash & Cash Equivalents | $1.18M | $98K |
| **Cash & Short-Term Investments** | $1.18M | $98K |
| **Total Current Assets** | $15.54M | $206K |
| Property, Plant & Equipment, Net | $3.09M | $3.05M |
| Other Non-Current Assets | $6.0K | $6.0K |
| **Total Non-Current Assets** | $5.24M | $6.16M |
| **Total Assets** | $20.78M | $6.37M |
| Accounts Payable | $2.0K | $3.0K |
| Short-Term Debt | $15.34M | -- |
| Other Current Liabilities | $3.45M | $3.29M |
| **Total Current Liabilities** | $34.81M | $12.13M |
| Other Non-Current Liabilities | $60K | $58K |
| **Total Non-Current Liabilities** | $10.87M | $30.76M |
| **Total Liabilities** | $45.68M | $42.88M |
| **Total Debt (incl. Leases)** | $15.44M | $175K |
| Common Stock | $1.0K | $1.0K |
| Retained Earnings | -$37.75M | -$33.08M |
| Accumulated Other Comp. Income | $682K | $1.12M |
| **Total Stockholders' Equity** | -$24.91M | -$36.52M |
| Total Equity | -$24.91M | -$36.52M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Net Income | -$4.67M | -$3.02M | -$4.40M |
| Depreciation & Amortization | $100K | $120K | $127K |
| Change in Payables | -$1.0K | $1.0K | -$2.0K |
| **Operating Cash Flow** | -$3.04M | -$3.62M | -$2.60M |
| **Investing Cash Flow** | -$13.51M | -- | $95K |
| Common Stock Issued | $17.77M | -- | -- |
| **Financing Cash Flow** | $17.63M | $1.99M | $2.03M |
| **Net Change in Cash** | $1.08M | -$1.64M | -$532K |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Return on Assets (ROA) | -22.5% | -47.4% | -- |
| Current Ratio | 0.45x | 0.02x | -- |
| Quick Ratio | 0.03x | 0.01x | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
